Navidea Biopharmaceuticals, Inc. — Cyborg Score 1/10
Challenged
Immunodiagnostic imaging and immunotherapeutics
Strategic Profile
The company's core technology platform, Manocept™, targets the CD206 mannose receptor on activated macrophages for diagnostic imaging and therapeutic delivery. Prior to bankruptcy, Navidea had generated meaningful revenues from the 2017 sale of Lymphoseek® rights to Cardinal Health. The bankruptcy auction process completed in January 2026 signals the end of the company as an independent operating entity.
Cyborg Score Rationale
The company is in Chapter 11 bankruptcy liquidation proceedings following an asset auction in January 2026, with stock trading at $0.0001. There is no viable path to operational recovery, and shareholder recovery is unlikely given the liability structure ($10M–$50M liabilities against $1M–$10M assets).
Top Insights
Filed Chapter 11 bankruptcy on October 1, 2025 with liabilities of $10M–$50M and assets of $1M–$10M
Asset auction occurred January 15, 2026; sale hearing completed January 26, 2026
Stock delisted and now trades OTC at $0.0001 as of June 2026
Previously monetized Lymphoseek® product via $98M sale to Cardinal Health in March 2017, with potential earn-outs through 2026
Named Competitors
Lymphoseek® — Sentinel lymph node imaging (acquired from Navidea in 2017)
Oncology imaging and diagnostics — Medical imaging and diagnostic technology
Rheumatoid arthritis diagnostics — In vitro and imaging diagnostics for inflammatory disease